AcuCort Expands Zeqmelit® Distribution to Denmark
AcuCort has successfully launched Zeqmelit® in Denmark, marking a significant step in its Nordic expansion.
Sammanfattning
AcuCort's Zeqmelit® has been launched in Denmark, aligning with market expectations. The company is also expanding internationally with strategic partnerships.
AcuCort AB, a Swedish pharmaceutical company, has taken a significant step forward in its Nordic expansion with the launch of Zeqmelit® in Denmark. This development follows the successful introduction of the product in Sweden, Norway, and Finland, completing the company’s presence in the Nordic region.
Zeqmelit®, a fast-dissolving oral film based on dexamethasone, is designed to treat severe allergic reactions, croup in children, nausea and vomiting during chemotherapy, and COVID-19 patients requiring supplemental oxygen. The innovative delivery method and proven efficacy of dexamethasone make Zeqmelit® a valuable addition to the Danish pharmaceutical market.
The initial order from Unimedic Pharma, AcuCort’s Nordic distribution partner, signifies a robust market interest. According to AcuCort’s CEO, Jonas Jönmark, the summer sales have met expectations, indicating a strong demand for Zeqmelit® in Denmark. Unimedic Pharma’s commitment and local presence have been crucial to this successful launch.
Beyond the Nordic region, AcuCort is eyeing international expansion. In June, the company signed two letters of intent (LOI) for strategic partnerships. The first is with Lunatus for distribution in the Middle East and Gulf states, while the second is with Glenmark Pharmaceuticals for Germany and five other European countries. These negotiations are expected to conclude by autumn, potentially opening new markets for AcuCort.
For investors, AcuCort’s strategic moves suggest a promising future. The successful launch in Denmark, coupled with potential international expansions, positions the company well for growth. Investors might consider holding their positions as the company continues to strengthen its market presence and explore new opportunities.
Källa
Sammanfattning
I april 2025 fick AcuCort en första order på Zeqmelit® från Unimedic Pharma för den danska marknaden, vilket markerade lanseringens början. Under sommaren började distributionen till danska apotek och efterfrågan har varit i linje med förväntningarna. AcuCorts VD, Jonas Jönmark, uttryckte att försäljningen har gått enligt förväntningar och att Unimedic Pharma har visat starkt engagemang. Lanseringen i Danmark är sista steget i AcuCorts etablering i Norden, där produkten redan finns i Sverige, Norge och Finland. I juni tecknade AcuCort två strategiska samarbetsavtal för internationell expansion, ett med Lunatus för Mellanöstern och Gulfstaterna och ett med Glenmark Pharmaceuticals för Tyskland och ytterligare fem europeiska länder. Förhandlingar pågår och väntas avslutas under hösten. AcuCort utvecklar och kommersialiserar Zeqmelit®, en snabblöslig munfilm baserad på dexametason, för behandling av olika medicinska tillstånd. Företaget är noterat på Spotlight Stock Market.
